BioInnovation Institute allocates €7.8M to help six companies bring technologies to market
Tech.eu Tamara Djurickovic
BII gave six companies another €7.8 million to push health, farm and energy tech toward market. Each now has €1.8 million from BII, plus its labs, investors and advisors in Copenhagen.
Based on reporting by Tech.eu, Tamara Djurickovic — read the original for the full story.
Summary, retelling and take written by AI under human oversight; images are AI-generated illustrations. How we work · Report an error
BioInnovation Institute is putting another €7.8 million behind six young companies, with each one getting €1.3 million to keep moving from research toward something that can actually be sold. The round spans healthcare, agriculture and sustainable energy, which is a neat reminder that “life science” at BII stretches well beyond hospitals.
The six companies had already taken €500,000 each from the institute, so this latest award brings BII’s total backing for each of them to €1.8 million. They also stay plugged into BII’s Copenhagen setup, including lab space, investors, advisers, strategic partners and help with business development and commercialisation. That support can matter as much as the cheque.
The roster is varied. PanTarg, a University of Copenhagen and Rigshospitalet spin-out, is working on an antibody-based cancer therapy that combines two targeted approaches, with pancreatic cancer among the first targets. 3Sonic, from Rigshospitalet and DTU, is building AI-powered 3D ultrasound so surgeons can assess cancer tissue during an operation. Inia Biosciences, which came out of Boston and Oxford, is chasing inflammatory disease treatments, starting with psoriasis.
The other three point in different directions. Yngvi Bio, from the University of Copenhagen, is developing biological pest control aimed at protecting crops while cutting environmental and biodiversity damage. Proxi Biotech, a spin-out from Statens Serum Institut, is working on vaccine-based immunotherapies for recurring bacterial infections, including recurrent Clostridium difficile. Sagava, from DTU, wants to turn waste into biogenic fuels and energy, with maritime emissions in its sights.
BII chief business officer Trine Bartholdy says the six have moved from early research toward technologies with commercial potential. That is the whole game here: not more lab trophies, but companies that can survive contact with the market. Plenty of institutes talk about impact; BII is at least writing cheques that force the issue.
My take — AI-written commentary, not fact-checked reporting
This is the kind of funding that actually helps: not giant, theatrical rounds, just enough money plus real infrastructure to drag science out of the petri dish. The interesting part is how many of these bets sit in awkward, useful places — cancer, infections, crops, fuels — where hype is loud but execution is brutal. That’s where an institute should lean in, not chase the easiest press release.
Read more about this at: Tech.eu